NCT06799533

A Study to Learn About the Study Medicine Called PF-08046031 in Advanced Melanoma and Other Solid Tumors

AN OPEN-LABEL PHASE 1 STUDY TO INVESTIGATE PF-08046031 IN ADULTS WITH ADVANCED MELANOMA AND OTHER SOLID TUMORS

• Status: Terminated
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 11 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This study will test the safety of a drug called PF-08046031 in participants with melanoma and other solid tumors that have no current approved treatment or have spread through the body. It will also study the side effects of this drug. A side effect is anything a drug does to the body besides treating the disease. The study will have 3 parts. Part A and B of the study will find out how much PF-08046031 should be given to participants. Part C will use the information from Parts A and B to see if PF-08046031 is safe and if it works to treat solid tumor cancers.

Conditions

• Malignant Melanoma
• Melanoma
• Metastatic Melanoma
• Solid Tumors

Interventions

Type	Name	Description
DRUG	PF-08046031	Given into the vein (IV; intravenous)

Timeline

• Start date: 2025-05-01
• Primary completion: 2026-02-23
• Completion: 2026-02-23
• First posted: 2025-01-29
• Last updated: 2026-03-18

Locations

11 sites across 5 countries: United States, France, Spain, Sweden, United Kingdom

Regulatory

• FDA-regulated drug study